Business, Management, Marketing, Money, Tax, Law, People

Cooley partner Caroline Hobson was quoted in The Lawyer about how the UK’s Competition and Markets Authority (CMA) is reforming its regulatory approach to be more pro-growth while reaffirming its commitment to preventing anticompetitive mergers and behavior. Hobson highlighted that the CMA’s procedural reform has been long overdue, as they had imposed significant costs and operational burdens on businesses, particularly in the merger review process. Read the article (subscription required)…

September 22, 2025 – Cooley advised PrizePicks, the largest daily fantasy sports operator in North America, on its definitive agreement for Allwyn International to acquire a majority stake in PrizePicks at an upfront enterprise value of $2.5 billion. If PrizePicks achieves certain performance metrics over the next three years, additional cash consideration under the agreement would result in an enterprise value of up to $4.15 billion. The transaction is anticipated…

As has been recently widely reported, President Donald Trump has called for an end to quarterly reporting with the Securities and Exchange Commission (SEC) in favor of a biannual reporting model, and the SEC has announced that it is prioritizing this proposal. While the future of the proposal is uncertain, one collateral consequence of its adoption that has received little attention so far is the potential effect on SEC Form…

On September 3, 2025, the US Food and Drug Administration (FDA) announced a new process to support the development of drugs intended to treat rare genetic diseases. The Rare Disease Evidence Principles (RDEP) process offers drug sponsors increased clarity on what constitutes “substantial evidence” of effectiveness for certain rare disease drug treatments, recognizing the unique challenges facing rare disease drug development, i.e., difficulties in enrolling large and randomized clinical trials. Because…

Santa Monica – September 16, 2025 – Cooley advised Dualitas Therapeutics, a biotechnology company pioneering next-generation bispecific antibody therapies for immunology and inflammation, on its $65 million Series A financing, to advance a portfolio of next-generation bispecific antibodies, including lead programs DTX-103 in allergic disease and DTX-102 for autoimmune disease, and to accelerate the development of Dualitas’ proprietary DualScreen BsAb discovery engine. The round was co-led by Versant Ventures and…

Palo Alto – September 18, 2025 – Cooley advised the underwriters of StubHub Holdings, a global secondary ticketing marketplace for live events, in connection with StubHub’s $800 million initial public offering (IPO). StubHub offered 34,042,553 shares of Class A common stock priced at $23.50 per share, with a 30-day option for the underwriters to purchase 5,106,382 additional shares. StubHub’s Class A common stock began trading on the New York Stock…

New York – September 2, 2025 – Cooley advised CHARM Therapeutics, a biotechnology company pioneering the next generation of precision oncology treatments through its proprietary artificial intelligence-driven drug discovery platform, on its $80 million Series B financing, to advance its next- generation menin inhibitor into clinical development. The round was co-led by New Enterprise Associates and SR One, with participation from existing investors OrbiMed, F-Prime, Khosla Ventures and NVIDIA. Lawyers…

Chicago – September 11, 2025 – Cooley advised Jump Crypto as a sponsor in connection with $1.65 billion in cash and stablecoin commitments for a private investment in public equity (PIPE) offering by Forward Industries, a global design company serving top-tier medical and technology companies, to initiate a Solana-focused digital asset treasury strategy, aligning Forward Industries with the fast-growing Solana ecosystem. In addition to Jump Crypto, the offering was led…

Palo Alto – September 17, 2025 – Cooley advised CalypsoAI, an adaptive artificial intelligence security platform that empowers enterprises to innovate safely, on its acquisition by F5, a global leader in delivering and securing every app and application programming interface. F5 will acquire all issued and outstanding shares of CalypsoAI, a private company with major operations in Dublin, Ireland, for $180 million in purchase consideration financed primarily with cash. The…

Cooley partner Melissa Gohlke was recognized as a Washington, DC, Rising Star in the National Law Journal’s annual Legal Awards. The National Law Journal’s Legal Awards highlight the top litigation and appellate work from the previous year. The law firms and attorneys recognized this year stood out for their work guiding clients through high-stakes litigation and for their cutting-edge approaches to environmental, social and corporate governance issues, along with their…

Hong Kong – August 29, 2025 – Cooley advised Harbour BioMed (HBM Holdings, HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in oncology and immunology, on its HK$517.75 million placement of new shares under general mandate. Harbour BioMed placed 45,022,000 new shares priced at HK$11.50 per share. Citi acted as the sole overall coordinator and sole placing agent for the placement. Partner…

New York – September 16, 2025 – Today, Cooley announced that Sean W. Brownridge has joined as a partner in the firm’s M&A group and new chair of its activism defense practice. Based in the firm’s New York office, Brownridge brings extensive experience counseling boards, management teams and investors on activist engagements, having guided some of the most high-profile proxy contests and campaigns in recent history. He is a widely…

Claire Keast-Butler, co-partner in charge of Cooley’s London office, was quoted in a Law.com article about the representation of women partners among UK law firms. Reflecting on Cooley’s top five ranking for women equity partner representation, Keast-Butler emphasizes the role the firm’s culture and professional development programs and initiatives play in driving meaningful change and representation. Read the article (subscription required) This content is provided for general informational purposes only,…

Cooley partner Patrick Van Eecke, co-chair of the firm’s global cyber/data/privacy practice, was quoted in a Bloomberg Law article about the European Union’s Data Act, which introduces regulations for smart devices and cloud-related service providers with a goal to expand data protection and give users more control over nonpersonal data. However, the act’s broad scope creates legal, contractual and technical difficulties, and Van Eecke highlighted how the Data Act is…

Cooley partners Mike Lincoln, vice chair of the firm, and Travis LeBlanc, co-chair of the cyber/data/privacy practice, have been named to Washingtonian magazine’s 2025 Tech Titans list. The annual list profiles the most influential and innovative leaders in the Washington, DC, tech sector – including lawyers, entrepreneurs, venture capitalists, cybersecurity experts and government officials. This marks LeBlanc’s second consecutive appearance on the list and Lincoln’s ninth recognition by the publication.…

New York – September 12, 2025 – Cooley advised LB Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases including schizophrenia, on its $285 million upsized initial public offering (IPO). LB Pharmaceuticals offered 19,000,000 shares priced at $15 per share, with a 30-day option for the underwriters to purchase an additional 2,850,000 shares. LB Pharmaceuticals’ common stock began trading on the Nasdaq Global Market on September…

New York – September 15, 2025 – Today Cooley announced that Tejal Shah has rejoined the firm as partner in its global litigation department. Shah returns to Cooley after nearly 12 years at the Securities and Exchange Commission (SEC), where she served in a series of increasingly senior leadership positions, culminating in her service as one of the New York office’s Associate Directors. Shah now becomes a core member of…

On September 8, the Office of the Comptroller of the Currency (OCC) issued two bulletins aimed at eliminating “politicized or unlawful debanking” by the banks it supervises. The OCC’s guidance is “consistent with” President Donald Trump’s recent executive order (EO) 14331, which directs “Federal banking regulators,” including the OCC, to remediate past instances and prevent against future acts of politicized or unlawful debanking.1 The first bulletin reminds banks that debanking activities…

The US Court of Appeals for the Sixth Circuit released its decision on the appeal of the Federal Communications Commission (FCC) data breach notification and reporting rules. The FCC order, which largely became effective in 2024, revised the definition of reportable data breaches, modified the requirements for customer notifications of breaches and required breaches to be reported to federal law enforcement and the FCC. The general effect of these changes…

Cooley partner Kenneth Krisko, head of the firm’s life sciences corporate partnering and licensing practice group, was quoted in a BioSpace article about biotechnology companies’ pipeline-in-a-product approach. Krisko discusses the power of combination therapies, how pipeline-in-a-product assets can allow companies to invest in research and development and manufacturing, and these products’ potential for extended revenue over time. Read the article This content is provided for general informational purposes only, and…

Cooley partner Helenanne Connolly was quoted in a Bloomberg article examining the financial and strategic costs of CEO dismissals from public companies. Connolly notes that departing executives often attempt to capitalize on the urgency of their departure by negotiating for more severance and additional perks, contributing to the overall cost. She also emphasizes the importance of companies’ coordination and execution when announcing the departure. Read the article This content is…

Cooley was shortlisted for Life Sciences Team of the Year as part of the Legal Business Awards 2025, which celebrate excellence, innovation and dedication across the legal profession. The nomination follows the firm’s representation of Autolus Therapeutics, a clinical-stage biopharmaceutical company that develops next-generation programmed T-cell therapies, in its strategic collaboration with BioNTech to advance both companies’ autologous CAR-T programs toward commercialization and in its $350 million underwritten offering. Read…

The California Air Resources Board (CARB) held a virtual public workshop on August 21 to refine implementation of the state’s corporate climate-disclosure laws – Senate Bills 253 and 261 (amended by SB 219). In advance of formal regulations now expected in December, guidance in this most recent webinar included technical topics, such as reporting formats and applicability tests, as well as the content of required disclosures, including minimum disclosure requirements…

San Diego – August 25, 2025 – Cooley advised MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, on its definitive merger agreement to acquire scPharmaceuticals for up to $360 million. This acquisition marks MannKind’s strategic expansion into cardiorenal medicine, establishing the company’s cardiometabolic business alongside its orphan lung division. Under the…

Cooley partner Amanda Main was quoted in an MLex article about the US Court of Appeals for the Ninth Circuit ruling that trade secret claims brought under the federal Defend Trade Secrets Act do not have to follow prediscovery disclosure rules established by the California Unified Trade Secret Act. Read the article (subscription required) This content is provided for general informational purposes only, and your access or use of the…

Washington, DC – August 25, 2025 – Today, Cooley announced that Elizabeth Prelogar has rejoined the firm as a partner in its global litigation department. Prelogar was the 48th Solicitor General of the United States and will lead Cooley’s Supreme Court and appellate practice group from Washington, DC. “Elizabeth is one of the most respected lawyers and oral advocates in the country,” said Cooley partner and CEO Rachel Proffitt. “Her…

President Donald Trump has signed a new executive order to “streamline commercial license and permit approvals” for US-based space businesses and ensure that US operators can efficiently launch, conduct missions in space and reenter US airspace. The goals of the executive order are to facilitate economic growth and national security, as well as accomplish federal space objectives. This order directs officials at the Department of Transportation (DOT), Council on Environmental Quality (CEQ),…

On August 22, 2025, the Consumer Financial Protection Bureau (CFPB) published an advance notice of proposed rulemaking (ANPR) seeking public comment on four substantive aspects of its Section 1033 rulemaking under the Dodd-Frank Act. The CFPB seeks input on: The definition of a third-party “representative” permitted to access data on a consumer’s behalf. Whether a data provider should be permitted to impose fees for access to consumer data and, if so,…

Cooley partner Elizabeth Prelogar was featured in Law.com and Law360, spotlighting her return to Cooley’s litigation department to lead the Supreme Court and appellate practice group out of the Washington, DC, office. In her interview with Law.com, Prelogar reflected on her earlier tenure at Cooley and her service as US Solicitor General from October 2021 to January 2025. Additionally, Prelogar described herself as a “litigator at heart” and shared insights…

Reston – August 28, 2025 – A Cooley team secured a finding of no interference-in-fact for client RSB Spine following a patent interference trial before Judge Richard G. Andrews of the US District Court for the District of Delaware against DePuy Synthes. In his August 27 trial opinion, Judge Andrews found in favor of RSB Spine and rejected DePuy’s interference counterclaim, concluding that DePuy did “not meet its preponderance of…

About Cooley LLP Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation. Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people. This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization…

San Francisco – August 28, 2025 – Cooley advised Framer, a professional website design platform that has quickly become the platform of choice for companies that want to ship their entire .com, on its $100 million Series D financing. The round was led by existing investors Meritech Capital and Atomico, valuing the company at $2 billion. Lawyers Peter Werner, Jeremy Ungerman Sears, Tamim Bazzi, Erin Wright and Karem Jarada led…

New York – August 28, 2025 – Cooley advised Eagle Pharmaceuticals, a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise, on its cooperation agreement with Nantahala Capital Management, a holder of approximately 38% of Eagle’s outstanding shares.    Lawyers Bill Roegge, Sarah Sellers, Marc Recht, Pat O’Connell, Asa Henin, Paul Alexander and Nathan Baum led the Cooley team advising Eagle. In connection with its entry…

The 2025 proxy season marked a turning point in the Securities and Exchange Commission’s (SEC) administration of shareholder proposals. Over the course of the season, the staff of the Division of Corporation Finance (staff) received a significant increase in no-action requests under Rule 14a-8 of the Securities Exchange Act of 1934, as amended (Rule 14a-8), granted relief to nearly 70% of requests and, under newly issued Staff Legal Bulletin 14M…

The Economic Crime and Corporate Transparency Act 2023 (ECCTA) is a landmark piece of legislation for regulatory authorities in the United Kingdom. It will become law on 1 September 2025. The Crown Prosecution Service (CPS) and Serious Fraud Office (SFO) are prepared and have set the tone for what we anticipate to be a significant change in the enforcement environment in the UK, as they published Joint Corporate Prosecution Guidance on…

A Cooley team led by lawyers Elizabeth Wright and Ethan Glass earned a shoutout on The American Lawyer’s Litigation Daily Litigator of the Week Runners-Up and Shout-Outs list for its representation of JetBlue. Last week, the US Court of Appeals for the First Circuit upheld a district court order denying a request for $34 million in attorney fees brought on behalf of private plaintiffs who had sued to block the…

Palo Alto – August 29, 2025 – Cooley advised Indian conglomerate Reliance Industries on its joint venture with Meta that will build and scale enterprise artificial intelligence (AI) solutions for enterprises in India and select international markets.   Under the agreement, Reliance and Meta have jointly committed to an initial investment of approximately $100 million to capitalize the joint venture. This partnership combines Reliance’s digital backbone with Meta’s open-source Llama models…

Cooley partner Brian French was featured in a Law.com article, offering insights into the mindset and skills that help make successful litigators. In the article, French reflects on his career path and why he joined Cooley, emphasizing the importance of relationship-building for associates early in their careers. Comparing litigation to a team sport, he notes that the best client outcomes result from working together as a single, cohesive team. French…

San Diego – September 2, 2025 – Cooley advised Enlaza Therapeutics, the first covalent biologics platform company, on its multi-target drug discovery collaboration with Vertex Pharmaceuticals, to utilize Enlaza’s proprietary War-Lock technology platform to develop small format drug conjugates and T-cell engagers for certain autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia.    Under the terms of the collaboration, Enlaza will receive $45 million inclusive of…

New York – September 3, 2025 – Cooley advised Thirty Madison, a specialty healthcare company offering high-quality virtual specialized care for patients experiencing a range of conditions, on its definitive agreement to be acquired by Remedy Meds in an all-stock transaction valued in excess of $500 million. Lawyers Izzy Lubarsky, Adam Dinow, Bill Roegge, Jenny Ge, Teddy Nimetz and Scott Rudin led the Cooley team advising Thirty Madison. Cooley previously…